NCT04984902 (CP026) is a NA clinical trial of Extracorporal therapy in Kidney Diseases, sponsored by ExThera Medical Europe BV.

Who is sponsoring NCT04984902?

NCT04984902 is sponsored by ExThera Medical Europe BV.

What drugs are being tested in NCT04984902?

Interventions in NCT04984902: Extracorporal therapy.

What condition does NCT04984902 study?

NCT04984902 studies Kidney Diseases, Kidney Transplant Infection, Kidney Transplant; Complications.

Is NCT04984902 still recruiting?

NCT04984902 is currently status unknown. Last updated 17 December 2021.

Last reviewed 2021-12-17 · How we verify

NCT04984902: CP026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduction of BK Viremia in Kidney Transplant Patients

Status unknown NA Last updated 17 December 2021

What this trial tests

NA trial testing Extracorporal therapy in Kidney Diseases in 40 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
1 February 2023

1 April 2023

Quick facts

Lead sponsor	ExThera Medical Europe BV
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 February 2022
Primary completion	1 February 2023
Estimated completion	1 April 2023
Sites	1 location across Germany

Drugs / interventions tested

Extracorporal therapy

Conditions studied

Kidney Diseases — all drugs for Kidney Diseases →
Kidney Transplant Infection — all drugs for Kidney Transplant Infection →
Kidney Transplant; Complications — all drugs for Kidney Transplant; Complications →

Sponsor

ExThera Medical Europe BV

Who can join

Adults 18 to 90, any sex, with Kidney Diseases or Kidney Transplant Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reduction of BK Viremia by treating kidney transplant patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting

Other ExThera Medical Europe BV trials

Trials by the same sponsor.

NCT04547257 — Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19 · NA · unknown
NCT04260789 — Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04984902 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ExThera Medical Europe BV
Last refreshed: 17 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04984902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing